📊 SPRO Key Takeaways
Is Spero Therapeutics, Inc. (SPRO) a Good Investment?
Spero Therapeutics demonstrates exceptional revenue growth of 431% YoY with achieved profitability (12.8% net margin) and an extremely strong balance sheet ($40.3M cash, minimal debt, 7.59x current ratio). However, negative operating cash flow of -$12.6M despite $8.6M net income raises significant accrual quality concerns that must be resolved to validate earnings sustainability.
Why Buy Spero Therapeutics, Inc. Stock? SPRO Key Strengths
- Exceptional revenue growth of 430.8% YoY indicates strong market traction and successful commercialization
- Fortress balance sheet with $40.3M cash, zero debt, and 7.59x current ratio provides substantial financial flexibility and 3+ years operating runway
- Profitable operations with 12.8% net margin and 9.5% operating margin demonstrate operating leverage and efficiency
SPRO Stock Risks: Spero Therapeutics, Inc. Investment Risks
- Negative operating cash flow of -$12.6M against $8.6M net income represents severe accrual quality concern with $21.2M gap requiring explanation
- Pharmaceutical sector inherently exposed to regulatory approvals, reimbursement changes, and competitive product threats
- Large working capital or receivables buildup embedded in revenue growth may not represent sustainable cash-generative business model
Key Metrics to Watch
- Operating cash flow trajectory - must demonstrate return to positive OCF to validate earnings quality and business sustainability
- Revenue composition by product and gross margin - assess if growth is sustainable and whether profitability scales
- Days sales outstanding and inventory turnover - monitor working capital efficiency and working capital requirements
Spero Therapeutics, Inc. (SPRO) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 7.59x current ratio provides a solid financial cushion.
SPRO Profit Margin, ROE & Profitability Analysis
SPRO vs Healthcare Sector: How Spero Therapeutics, Inc. Compares
How Spero Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Spero Therapeutics, Inc. Stock Overvalued? SPRO Valuation Analysis 2026
Based on fundamental analysis, Spero Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Spero Therapeutics, Inc. Balance Sheet: SPRO Debt, Cash & Liquidity
SPRO Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Spero Therapeutics, Inc.'s revenue has grown significantly by 310% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.27 indicates the company is currently unprofitable.
SPRO Revenue Growth, EPS Growth & YoY Performance
SPRO Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | -$7.4M | $-0.13 |
| Q2 2025 | N/A | -$1.7M | $-0.03 |
| Q1 2025 | $12.0K | -$12.7M | $-0.24 |
| Q3 2024 | $65.0K | N/A | $-0.06 |
| Q2 2024 | $114.0K | -$11.9M | $-0.23 |
| Q1 2024 | $140.0K | -$12.7M | $-0.24 |
| Q3 2023 | $1.1M | -$3.2M | $-0.06 |
| Q2 2023 | $788.0K | -$11.9M | $-0.23 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Spero Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
SPRO SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Spero Therapeutics, Inc. (CIK: 0001701108)
📋 Recent SEC Filings
❓ Frequently Asked Questions about SPRO
What is the AI rating for SPRO?
Spero Therapeutics, Inc. (SPRO) has an AI rating of BUY with 68% confidence, based on fundamental analysis of SEC EDGAR filings.
What are SPRO's key strengths?
Claude: Exceptional revenue growth of 430.8% YoY indicates strong market traction and successful commercialization. Fortress balance sheet with $40.3M cash, zero debt, and 7.59x current ratio provides substantial financial flexibility and 3+ years operating runway.
What are the risks of investing in SPRO?
Claude: Negative operating cash flow of -$12.6M against $8.6M net income represents severe accrual quality concern with $21.2M gap requiring explanation. Pharmaceutical sector inherently exposed to regulatory approvals, reimbursement changes, and competitive product threats.
What is SPRO's revenue and growth?
Spero Therapeutics, Inc. reported revenue of $66.8M.
Does SPRO pay dividends?
Spero Therapeutics, Inc. does not currently pay dividends.
Where can I find SPRO SEC filings?
Official SEC filings for Spero Therapeutics, Inc. (CIK: 0001701108) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is SPRO's EPS?
Spero Therapeutics, Inc. has a diluted EPS of $0.15.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is SPRO a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Spero Therapeutics, Inc. has a BUY rating with 68% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is SPRO stock overvalued or undervalued?
Valuation metrics for SPRO: ROE of 14.5% (sector avg: 15%), net margin of 12.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy SPRO stock in 2026?
Our dual AI analysis gives Spero Therapeutics, Inc. a combined BUY rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is SPRO's free cash flow?
Spero Therapeutics, Inc.'s operating cash flow is $-12.6M, with capital expenditures of $0.0. FCF margin is -18.9%.
How does SPRO compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 12.8% (avg: 12%), ROE 14.5% (avg: 15%), current ratio 7.59 (avg: 2).